Literature DB >> 19351930

Rare neurological condition linked to newer monoclonal antibody biologics.

Bridget M Kuehn.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19351930     DOI： 10.1001/jama.2009.451

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  6 in total

1.  What is the role of vedolizumab in the era of anti-TNF agents?

Authors:  Fong-Kuei F Cheng; Leon P McLean; Raymond K Cross
Journal:  Ann Transl Med       Date:  2014-01

Review 2.  A product review of vedolizumab in inflammatory bowel disease.

Authors:  Robert Battat; Parambir S Dulai; Vipul Jairath; Niels Vande Casteele
Journal:  Hum Vaccin Immunother       Date:  2019-05-07       Impact factor: 3.452

Review 3.  Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.

Authors:  Robert Battat; Christopher Ma; Vipul Jairath; Reena Khanna; Brian G Feagan
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

Review 4.  Adverse events in IBD: to stop or continue immune suppressant and biologic treatment.

Authors:  Leon P McLean; Raymond K Cross
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2014-02-04       Impact factor: 3.869

Review 5.  Vedolizumab for the treatment of ulcerative colitis and Crohn's disease.

Authors:  Leon P McLean; Terez Shea-Donohue; Raymond K Cross
Journal:  Immunotherapy       Date:  2012-09       Impact factor: 4.196

Review 6.  Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy.

Authors:  Noritaka Takatsu; Takashi Hisabe; Daijiro Higashi; Toshiharu Ueki; Toshiyuki Matsui
Journal:  Core Evid       Date:  2020-04-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.